宏噬细胞可通过 HO-1 阻碍 T 细胞进入肿瘤
'Gatekeeper' cells can restrict the immune response to cancer
研究发现,肿瘤周围的巨噬细胞可通过产生 HO-1 阻碍 T 细胞进入肿瘤,化疗虽能吸引 T 细胞向肿瘤移动,但巨噬细胞仍可形成屏障。阻断 HO-1 可增强化疗效果,使更多 T 细胞进入肿瘤,有助于免疫治疗。
A new study led by King's College London has found that chemotherapy helps attract a specific population of immune cells called stem-like T cells toward tumors. The research, published in Cell Stem Cell, found that macrophages around tumor blood vessels can act as a barrier, limiting the T cells' ability to enter. By blocking an enzyme called heme oxygenase-1 (HO-1) in these macrophages, the researchers were able to reduce this barrier, allowing more stem-like T cells to enter the tumor and contribute to an antitumor immune response.
The findings could help explain differences in responses to chemotherapy and may also have implications for immunotherapies that depend on stem-like T cells.
Macrophages limit T cell entry
T cells play an important role in the body's ability to recognize and attack cancer. Certain "stem-like" T cells are particularly important because they can renew themselves and develop into other T cells that can attack cancer cells. They can therefore help sustain an immune response against a tumor over time and have also been shown to play an important role in responses to immunotherapy.
However, while we know these cells can be important in the immune response to cancer, less is understood about how they enter tumors and the barriers that may hinder their entry. The researchers found that a specific population of a type of white blood cell called macrophages, located around the tumor's blood vessels, can act as a kind of "gatekeeper," controlling whether stem-like T cells can move from the bloodstream into the tumor.
They found that chemotherapy changes the tumor environment and increases signals that attract stem-like T cells toward the tumor. However, the cells still struggled to enter the tumor because of the barrier created by the macrophages.
"It was an exciting and unexpected discovery that, despite its complexity, the tumor microenvironment can be targeted to help chemotherapy work better and engage the stem-like T cells," said lead author Dr. Tik Shing Cheung, a research associate at King's College.
HO-1 inhibition complements chemotherapy
The macrophages produce an enzyme called heme oxygenase-1 (HO-1). When the researchers blocked HO-1, this barrier was reduced, allowing more stem-like T cells to enter the tumor.
HO-1 inhibition alone was not sufficient to control tumor growth. However, when combined with chemotherapy, the two approaches worked together, as chemotherapy helped attract the stem-like T cells toward the tumor, while HO-1 inhibition helped them enter.
The researchers found that the T cells were recruited through a signaling pathway involving the chemokine CXCL12 and its receptor CXCR4. CXCL12 acts as a signal that attracts the T cells, while CXCR4 allows the T cells to respond to it.
Testing the mechanism across cancers
Further research is needed to understand whether this mechanism operates in different types of cancer and whether the findings could eventually be translated into treatments for patients.
"Stem-like T cells have become a really important cell of interest in the antitumor immune response. The observation that macrophages that reside close to blood vessels can hinder this effect via HO-1 is important as it provides a therapeutic target to improve their entry to tumors, which may improve responses to other immunotherapies, such as immune checkpoints, which rely on these cells for their therapeutic effect," said senior author James Arnold, professor of tumor immunology at King's College London.
The findings of this study provide new insight into how the tumor environment can control the immune response and could help researchers better understand how to enable cancer-fighting T cells to reach tumors.
Publication details
Tik Shing Cheung et al., Perivascular macrophages restrict CXCR4-dependent accumulation of stem-like CD8+ T cells in tumors and limit chemotherapy efficacy, Cell Stem Cell (2026). DOI: 10.1016/j.stem.2026.10.007
Journal information: Cell Stem Cell
Key medical concepts
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: 'Gatekeeper' cells can restrict the immune response to cancer (2026, November 5) retrieved 5 November 2026 from https://medicalxpress.com/news/2026-11-gatekeeper-cells-restrict-immune-response.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com